# Intranasal Insulin for Posttraumatic Stress Disorder

> **NCT04044534** · PHASE2 · RECRUITING · sponsor: **VA Connecticut Healthcare System** · enrollment: 20 (estimated)

## Conditions studied

- PTSD

## Interventions

- **DRUG:** Intranasal insulin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04044534
- **Lead sponsor:** VA Connecticut Healthcare System
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-31
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04044534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04044534, "Intranasal Insulin for Posttraumatic Stress Disorder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04044534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*